Evidence map›Paper›PMID 30130999›Full record

ReviewNucleus (Austin, Tex.)2018

Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes.

Giuseppe Boriani, Elena Biagini, Matteo Ziacchi, Vincenzo Livio Malavasi, Marco Vitolo, Marisa Talarico, Erminio Mauro, Giulia Gorlato, Giovanna Lattanzi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nucleus (Austin, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Co-morbid monogenic disorders at chromosome region 1q2: LMNA- and FLG-related disorders in a patient referred for assessment of joint hypermobility.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2025
    Article
  3. Review
  4. Cardiac pacing and lead devices management: 25 years of research at EP Europace journal.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Understanding the molecular basis of cardiomyopathy.American journal of physiology. Heart and circulatory physiology · 2022
    Review
  9. Effect of Occurrence of Lamin A/C (Frontiers in cardiovascular medicine · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Pulmonary vein isolation treats symptomatic AF in a patient with Lamin A/C mutation: case report and review of the literature.Clinical research in cardiology : official journal of the German Cardiac Society · 2020
    Review
  14. Cardiac diseases as a predictor warning of hereditary muscle diseases. The case of laminopathies.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2019
    Article
  15. The Cutting Edge: The Role of mTOR Signaling in Laminopathies.International journal of molecular sciences · 2019
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Giuseppe Boriania Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy.
Elena Biaginib Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine , University of Bologna, S.Orsola-Malpighi University Hospital , Bologna , Italy.
Matteo Ziacchib Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine , University of Bologna, S.Orsola-Malpighi University Hospital , Bologna , Italy.
Vincenzo Livio Malavasia Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy.
Marco Vitoloa Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy.
Marisa Talaricoa Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy.
Erminio Mauroa Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy.
Giulia Gorlatoa Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , University of Modena and Reggio Emilia, Policlinico di Modena , Modena , Italy.
Giovanna Lattanzic CNR Institute of Molecular Genetics , Unit of Bologna , Bologna , Italy.
University of Modena and Reggio Emilia · ITPoliclinico di Modena · ITUniversity of Bologna · ITIstituto Ortopedico Rizzoli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lamin A/C gene mutations can be associated with cardiac diseases, usually referred to as 'cardiolaminopathies' characterized by arrhythmic disorders and/or left ventricular or biventricular dysfunction up to an overt picture of heart failure. The phenotypic cardiac manifestations of laminopathies are frequently mixed in complex clinical patterns and specifically may include bradyarrhythmias (sinus node disease or atrioventricular blocks), atrial arrhythmias (atrial fibrillation, atrial flutter, atrial standstill), ventricular tachyarrhythmias and heart failure of variable degrees of severity. Family history, physical examination, laboratory findings (specifically serum creatine phosphokinase values) and ECG findings are often important 'red flags' in diagnosing a 'cardiolaminopathy'. Sudden arrhythmic death, thromboembolic events or stroke and severe heart failure requiring heart transplantation are the most dramatic complications of the evolution of cardiolaminopathies and appropriate risk stratification is clinically needed combined with clinical follow-up. Treatment with cardiac electrical implantable devices is indicated in case of bradyarrhythmias (implant of a device with pacemaker functions), risk of life-threatening ventricular tachyarrhythmias (implant of an ICD) or in case of heart failure with wide QRS interval (implant of a device for cardiac resynchronization). New technologies introduced in the last 5 years can help physicians to reduce device-related complications, thanks to the extension of device longevity and availability of leadless pacemakers or defibrillators, to be implanted in appropriately selected patients. An improved knowledge of the complex pathophysiological pathways involved in cardiolaminopathies and in the determinants of their progression to more severe forms will help to improve clinical management and to better target pharmacological and non-pharmacological treatments.

Indexed as

Clinical Decision-MakingArrhythmias, CardiacHeart DiseasesHumansLamin Type AMusculoskeletal DiseasesLamin Type ALMNA protein, humanArrhythmiaemerinEmery-Dreifuss muscular dystrophyheart failurelamin A/Cstrokesudden cardiac deaththromboembolism

Identifiers

PMID30130999
PMCPMC6244733
OpenAlexW2888230358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.